The plasma small dense LDL-cholesterol calculation formula proposed by Srisawasdi et al is not applicable to Koreans who are healthy or have metabolic syndrome. by 김윤정 et al.
Correspondence
c o r r e s p o n d e n c e
754     Am J Clin Pathol  2012;138:754-758 © American Society for Clinical Pathology
The Plasma Small Dense LDL-Cholesterol Calculation Formula Proposed by Srisawasdi et al  
Is Not Applicable to Koreans Who Are Healthy or Have Metabolic Syndrome
DOI: 10.1309/AJCPKKOGEJ86LGJU
To the Editor
We read with great interest the article by Srisawasdi 
et al1 regarding a new formula for the estimation of small, 
dense, low-density lipoprotein cholesterol (sdLDL-C) levels. 
The investigators studied the correlation between classic 
lipid measures and sdLDL-C measured directly via a newly 
developed homogeneous method, in a total of 220 subjects 
without liver or renal disease. Using the data, they deduced 
the following simple equation for calculating sdLDL-C: 
sdLDL-Cmg/dL = 0.580 (non–HDL-C) + 0.407 (dLDL-C) –
0.719 (cLDL-C) – 12.05
where cLDL-C indicates calculated low-density lipoprotein 
cholesterol; dLDL-C, direct low-density lipoprotein 
cholesterol; and HDL-C, high-density lipoprotein cholesterol.
According to their results, the coefficient of 
determination (R2) between directly measured sdLDL-C 
and the calculated value was 0.878 while their mean 
difference and SD of the difference were only 0.85 mg/dL 
(0.02 mmol/L) and 9.2 mg/dL (0.24 mmol/L), respectively.1 
Further, they indicated that this formula provides a good 
estimate of sdLDL-C levels in healthy Thai individuals 
regardless of differences in sex, age group, creatinine level, 
or state of glucose intolerance.
Prompted by the article by Srisawasdi et al,1 we 
conducted a validation study of the sdLDL-C equation in 
healthy Koreans and in patients with metabolic syndrome 
(MetS) to determine whether it can be applied to the Korean 
population in general and to a specific patient group with 
abnormal lipoprotein metabolism. A total of 318 Korean 
subjects (163 men and 155 women) with MetS were 
randomly selected from the Korean Metabolic Syndrome 
Research Initiatives (KMSRI)–Seoul cohort study.2 A total of 
360 age- and sex-matched healthy controls (181 men and 179 
women) were also randomly selected from the same cohort. 
We excluded subjects younger than 20 years or older than 70 
years of age, those with a history of familial lipid disorders 
or dyslipidemia-related diseases, as well as individuals 
with renal disease, hepatic disease, infectious diseases, or 
malignancy. MetS was diagnosed according to the National 
Cholesterol Education Program Adult Treatment Panel 
definition of metabolic syndrome modified for the Asian 
population.3 All subjects completed a lifestyle questionnaire 
and anthropometric survey, and all biochemical samples were 
collected in accordance with the study protocol approved by 
the institutional review board of Severance Hospital, Yonsei 
University, Seoul, Korea. 
We determined sdLDL-C levels using thawed serum 
samples stored frozen below –70°C. Serum sdLDL-C levels 
were measured using a homogeneous enzymatic assay (Denka 
Seiken, Tokyo, Japan) on a Hitachi-7600 analyzer (Hitachi, 
Tokyo, Japan). The Randox reagents used by Srisawasdi 
et al are essentially the same as the Denka Seiken reagents; 
however, they used a different instrument (Dimension RxL 
Max, Siemens Medical Solution Diagnostics, Tarrytown, 
NJ).1 None of the patients enrolled in the present study had 
triglyceride levels higher than 400 mg/dL (4.52 mmol/L), 
and the results of a comparison between directly measured 
sdLDL-C and calculated sdLDL-C levels according to 
subgroup are shown ❚Table 1❚. We used PASW Statistics 
software version 18.0.0 (SPSS, Chicago, IL) for correlation 
and multiple linear regression analysis. We also used SAS 
version 9.1.3 (SAS Institute, Cary, NC) for comparison of 
Pearson correlation or regression coefficients.
In the overall study population, the equation slightly 
overestimated the sdLDL-C level (mean difference, 
3.11 ± 0.43 mg/dL). The R2 value corresponding to the 
relationship between the directly measured sdLDL-C 
values and those computed using the proposed equation 
was 0.629, which is much lower than the R2 of 0.878 
reported by Srisawasdi et al.1 The lower explanatory power 
of the equation may be related to basic differences in study 
designs such as the ethnicity of the study populations 
(Thai vs Korean) or the lipid measurement methods 
(Siemens vs Roche for triglycerides; Siemens vs Sekisui 
for total cholesterol, HDL-C, and LDL-C). Srisawasdi et al 
claimed that the lipid test showed acceptable performance 
according to the Lipid Standardization Program (LSP) 
developed by the Centers for Disease Control and 
Prevention (Atlanta, GA). Although our laboratory does 
not participate in LSP, we are enrolled in the College of 
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value was still inferior to that reported by Srisawasdi 
et al.1 However, the slightly better correlation detected 
between directly measured and calculated sdLDL-C levels 
in women compared with men (Table 1) may have played 
a role in the difference between our study and that of 
Srisawasdi et al because their gender ratios were different 
from ours.
Our findings suggest that the equation proposed by 
Srisawasdi et al1 is not directly applicable to the Korean 
population. Furthermore, the performance of the proposed 
equation was worse in the MetS group compared with 
the healthy group, with a significant difference between 
calculated and directly measured values (Table 1), 
which obviates its generalization to patients with MetS. 
Therefore, to determine a generally applicable formula 
for the estimation of sdLDL-C, the correlation between 
conventional lipid parameters and sdLDL-C should be 
extensively evaluated across different ethnic and disease 
groups. In addition, standardized methods should be used 
for conventional lipid measurement.
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and our method demonstrated acceptable performance 
according to their standards.
The equation also overestimated sdLDL-C levels in both 
the healthy group (3.28 ± 0.48 mg/dL [0.08 ± 0.01 mmol/L]) 
and the MetS group (2.92 ± 0.73 mg/dL [0.07 ± 0.01 
mmol/L), and the biases in each group were not significantly 
different (Table 1). Although the correlation between the 
directly measured and calculated sdLDL-C values was 
significant in both groups (healthy group, r = 0.809, P < 
.001; MetS group, r = 0.688, P < .001), the slope and offset 
were quite different (P = .0324 and P < .0001, respectively), 
and R2 was better in the control group (0.654 vs 0.473, P = 
.0003), as shown in Table 1. This implies that the proposed 
equation may not be suitable for the calculation of sdLDL-C 
in Korean patients with MetS. 
We performed multiple linear regression analysis using 
lipid profiles as the only independent variables for each 
disease group to generate a formula based on our data. In 
the healthy control group, dLDL-C showed collinearity 
(variance inflation factor >10) with both cLDL-C and total 
cholesterol, and the correlation coefficient value of dLDL-C 
with sdLDL-C was not significant. We therefore excluded 
dLDL-C from the regression analysis and obtained the 
following equations:
sdLDL-Cmg/dL = 0.690 [non–HDL-C] – 0.410 [cLDL-C] –
15.276, R2 = 0.714
sdLDL-Cmg/dL = 0.084 [TG] + 0.281 [TC] – 0.251 [HDL-C] – 
17.236, R2 = 0.714
where TC indicates total cholesterol and TG, triglyceride.
In patients with MetS, the aforementioned collinearity 
between cLDL-C, TC, and dLDL-C was not found, and the 
equation deduced for this group showed a lower R2 of 0.640. 
The R2 value for the overall study population was 0.711.
Although we achieved a better R2 value by generating 
a linear equation from our own data, the observed R2 
❚Table 1❚
Regression Analysis Between Measured and Calculated sdLDL-C* Values According to Subgroups
  Coefficients (95% Confidence Interval)
Group n r SE, mg/dL Bias, mg/dL Slope Intercept
Sex      
   Male 344 0.711  11.385  2.46  0.630 (0.564-0.697) 18.290 (15.204-21.375)
   Female 334 0.877  6.877  3.78  0.730 (0.687-0.773) 13.415 (11.709-15.121)
   P  <.0001†  .1208‡ .0159§ .0058§
Disease status      
   Healthy 360 0.809  7.575  3.28  0.669 (0.619-0.720) 13.953 (12.143-15.762)
   MetS 318 0.688  10.646  2.92  0.577 (0.510-0.645) 22.896 (19.497-26.295)
   P  .0003†  .6805‡ .0324§ <.0001§
All subjects 678 0.793  9.477  3.11  0.682 (0.642-0.722) 15.608 (13.897-17.319)
MetS, metabolic syndrome; sdLDL-C, small, dense, low-density lipoprotein-cholesterol; SE, standard error of estimate.
* sdLDL-C calculated according to the formula proposed by Srisawasdi et al.1
† Pearson correlation coefficient difference of either sex or disease status subgroups using Fisher z transformation. 
‡ Student t test.
§ Regression coefficient (slope and intercept) difference of either sex or disease status subgroup using t test.
Correspondence
756     Am J Clin Pathol  2012;138:754-758 © American Society for Clinical Pathology
References
 1. Srisawasdi P, Chaloeysup S, Teerajetgul Y, et al. Estimation 
of plasma small dense LDL cholesterol from classic lipid mea-
sures. Am J Clin Pathol. 2011;136:20-29.
 2. Lee M, Jang Y, Kim K, et al. Relationship between HDL3 
subclasses and waist circumferences on the prevalence of 
metabolic syndrome: KMSRI-Seoul Study. Atherosclerosis. 
2010;213:288-293.
 3. Tan C-E, Ma S, Wai D, et al. Can we apply the National 
Cholesterol Education Program Adult Treatment Panel defi-
nition of the metabolic syndrome to Asians? Diabetes Care. 
2004;27:1182-1186.
The Authors’ Reply
We thank Dr Cho and colleagues for their interesting 
validation study on our formula for the estimation of small, 
dense, low-density lipoprotein cholesterol (sdLDL-C) in 
a Korean population. They found that our equation was 
not directly applicable to a Korean population because of 
overestimation of sdLDL-C in both healthy subjects and 
patients with metabolic syndrome. 
Several reasons may be responsible for the disagreement 
between our study and the study by Cho et al. First, as we 
mentioned in our article, the variation in the LDL-C results 
may have contributed to the variation in calculated sdLDL-C. 
The principle of the LDL-C method used in our study 
(Siemens Medical Solution Diagnostics, Tarrytown, NY) was 
liquid selective detergent method that may differ from the 
Sekisui LDL-C assay (Sekisui Medical, Tokyo, Japan) used 
by Cho et al, which was based on selective solubilization 
using differences in affinity between lipoproteins and 
detergents. Because of the difference in methods, their results 
are not comparable. Second, the stability of sdLDL-C in 
samples should be of concern. Although Ito et al1 found that 
the sdLDL-C particles in serum samples were stable for at 
least 4 days in a refrigerator, we did not know the stability 
of sdLDL-C in the frozen sample. In the Korean Metabolic 
Syndrome Research Initiatives (KMSRI)-Seoul Study,2 the 
study samples from this cohort may have been stored at 
temperatures below –70°C since 2006 to 2007. Using frozen 
samples may have introduced a matrix effect on their results. 
Natural aggregation of lipoproteins may have occurred in 
samples stored for too long, which may have a bigger effect 
on sdLDL-C than on other lipoprotein. Using inappropriate 
samples might provide the low measured sdLDL-C 
concentration. Lastly, Cho et al introduced selection bias 
in their patient selection, with an inadequate distribution in 
lipid values. According to the KMSRI-Seoul Study,2 we 
found that the range of total cholesterol and LDL-C levels in 
Korean samples may be lower and tighter than those in our 
study; (235.7 ± 76.9 mg/dL [6.1 ± 2 mmol/L] vs 195.9 ± 37.8 
mg/dL [5.0 ± 0.97 mmol/L] for total cholesterol and 158.8 ± 
72.7 mg/dL [4.1 ± 1.9 mmol/L] vs 117.8 ± 31.6 mg/dL [3.0 ± 
0.81 mmol/L] for LDL-C). It is implied that mean sdLDL-C 
concentrations obtained in the KMSRI-Seoul study were 
not only lower than ours, but the spread of our values was 
much greater than in their study. This condition by itself may 
have resulted in differences in the results obtained via linear 
regression, but it also had a major effect on the correlation 
coefficient obtained in their study. If the tightness in the 
range of results is typical for the population being screened 
in Korea, their comments may be of particular interest; 
however, we would suggest that they investigate a broader 
range of values. 
We absolutely agree that our proposed equation should 
be used across different ethnic and disease groups and also 
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To the Editor
We read with interest the report by Fritsma et al1 on 
the recommendations to use more than 1 reagent to screen 
for lupus anticoagulant (LA) in a hemostasis laboratory. 
Activated partial thromboplastin time (APTT) reagents 
supplied by different commercial sources are becoming 
increasingly specific not only for the presence of LA 
but also for different levels and types of coagulation 
factors and heparin.2,3 The different factors affecting the 
sensitivity of these reagents are the type and concentration 
of phospholipids, type of activators, and the procedures 
followed in their preparation. Moreover, no data exist on 
the sensitivity of these reagents to various other clinical 
conditions associated with prolongation of APTT, like 
hypoalbuminemia, presence of active coagulation factors in 
circulation, microparticles, and monoclonal gammopathy. 
To add some more information to that published 
by Fritsma et al, we advise that the 2 APTT reagents 
recommended for screening of LA should be from the 
same manufacturer. The diagnosis of LA is suspected 
mainly based on the difference in clotting times 
between low and high phospholipid reagents. Because 
different manufacturers use different concentrations of 
phospholipids, lupus-sensitive and lupus-insensitive 
reagents from different sources can give negative results 
on some occasions, even in the presence of LA. As rightly 
pointed out by our colleagues, a laboratory needs to have 
a good screening test for LA to avoid the use of more 
expensive confirmatory tests.
Another important point to mention here is the 
selection of APTT reagents for screening of factor VIII 
inhibitors. One of the major issues in measurement of these 
inhibitors with the conventional Bethesda assay or the 
modified assays is LA interference in a small percentage 
of patients with hemophilia.4-6 So ideally lupus-insensitive 
APTT reagents should be used for detecting factor VIII 
or IX inhibitors to differentiate between LA and specific 
inhibitors to coagulation factors. 
With more studies reporting the need for a clinical 
laboratory to use multiple APTT reagents, the question 
arises as to how many reagents should be procured to 
provide accurate results for the common coagulation tests. 
It is prudent to keep at least 2 types of APTT reagents; 
for routine factor assays and inhibitor assays, a lupus-
insensitive reagent should preferentially be used. In patients 
receiving heparin therapy, LA-insensitive APTT reagents 
should be used. In patients clinically suspected of lupus 
inhibitors, LA-sensitive APTT reagents should be used. 
However while reporting such results, the clinical history 
of patients also should be integrated with this report, and 
remarks should include possible use of other tests clarifying 
prolonged APTT without apparent reason when mixing 
studies have produced either no or incomplete corrections.
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The Authors’ Reply
We thank Drs Shetty and Ghosh for their comments. 
The development of activated partial thromboplastin time 
(APTT) reagent is complex and requires manufacturers to 
balance the effects of phospholipids, particulate activators, 
and matrix. The APTT reagent selection process at the 
local laboratory must weigh the needs of their patient 
population, including concerns about the prevalence of 
lupus anticoagulant (LA), possibility of coagulopathies, the 
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potential for encountering specific inhibitors, and the extent 
and types of anticoagulants (such as heparin and direct 
thrombin inhibitors) used at the institution. The prevalence 
of low-molecular-weight heparin therapy among outpatients 
may also be considered. Like Drs Shetty and Ghosh, we 
recommend an LA-insensitive reagent when the purpose 
of the APTT is primarily to monitor heparin therapy. We 
note also that the selection and application of reagents for 
coagulopathy screening, anticoagulation monitoring, and 
LA detection is a worldwide concern.
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